Greenwich Lifesciences Inc GLSI

$19.00 +0.69 (3.77%)

Valuation

Market cap
268,754,000
Revenue TTM
$0
Net income TTM
$-19,360,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
124,000
Avg volume
130,164
Day's range
$18.08 – $19.50
Shares out
14,678,000
Stochastic %K
89%
Beta
1.46
Analysts
Strong Sell
Price target
$57.00

Price

Company profile

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I...

Show more

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.

Industry
Biotechnology
Sector
Healthcare
Phone
832-819-3232
Website
https://greenwichlifesciences.com
Address
Building 14, 3992 Bluebonnet Dr., Stafford, United States

Latest news

Stocktwits

doc123266 Oct 30, 10:12 AM
$GLSI
0 replies
doc123266 Oct 30, 10:09 AM
$GLSI I know I’m repeating myself but this treatment may be useful with other her2 cancers. I was just doing some digging. This is from September.
0 replies
Toontje1 Oct 30, 8:22 AM
$GLSI If Patel holding 100% of his stock and buying more with his own money to negotiate a top-tier partnership is 'bad' for investors, then peak StockTwits logic has hit a new low. A smart partner deal at high valuation protects the downside and maximizes buyout value. If that makes him 'arrogant', I hope he stays arrogant all the way to $10B.
0 replies
Doktore5 Oct 30, 7:48 AM
$GLSI Prove me wrong please. @Toontje1 Patel is an arrogant prick who wont sell a dime of his stock because he doesnt care about investors so he will have a partner and run his money up
1 replies
Toontje1 Oct 30, 1:40 AM
$GLSI Funny that they did mention the big boys. One of them is a potential partner or buyer. 🤌
1 replies
lowpricedstocks Oct 29, 10:02 PM
$GLSI It’s all 100% interim. No company going to invest 10B takeover offer into 300M market cap before interim. Reflected in share price. Patel won’t make partnership offer before first interim that’s close at hand when superiority interim brings instant 5-10B offers September interview by Patel on website for the latest
1 replies
paulstoxk Oct 29, 8:37 PM
$GLSI nice week!
0 replies
Rolltide2020 Oct 29, 8:01 PM
$GLSI https://youtu.be/cvg5mbM6FGs?si=AFJfM7WVXZpGkkvz
1 replies